According to filings with the U.S. Securities and Exchange Commission, US Pharmatech is raising up to $3,403,700.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About US Pharmatech
US Pharmatech Inc. (USP) is a leading nutraceutical and supplement manufacturer, specializing in OEM and private label services. The company offers a comprehensive, one-stop solution for supplement manufacturing, encompassing everything from creation and packaging to labeling and shipping. With a robust R&D department, US Pharmatech has developed over 40,000 formulas, covering a wide range of product forms including solid tablets and liquid solutions. Headquartered in Las Vegas and Cerritos, California, USP also maintains a global presence with offices in Korea, Japan, and China.

To learn more about US Pharmatech, visit https://uspharmatech.com/
US Pharmatech Linkedin Page: https://www.linkedin.com/company/uspharmatechinc/

Contact:
DongJun Lee, Chief Executive Officer
725-373-7060

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.